Cd39 apc

Manufactured by BioLegend

Sourced in United States

CD39-APC is a fluorochrome-conjugated monoclonal antibody that binds to the CD39 (Ectonucleoside triphosphate diphosphohydrolase 1) cell surface protein. CD39 is an enzyme that catalyzes the hydrolysis of extracellular nucleotides, playing a role in regulating immune responses.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Anti-CD39-APC (3 citations)

3 protocols using cd39 apc

Comprehensive Immune Phenotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following anti-human antibodies were used for staining: CD3-FITC, CD3- Alexa Fluor 700, CD8a-Alexa Fluor700, CD4-Percp-Cy5.5, CD4-Alexa Fluor 700, CD25-PE, CD25-PE-Cy7, Foxp3-FITC, Foxp3- Percp-Cy5.5, Foxp3-BV421, CD127-APC, CD39-APC, LAP-PE, IL-10-PE, TIM-3-PE, TIM-3-BV421, IFN-γ receptor-PE, IFN-γ- APC, Granzyme B-PE-dazzle E, PD-1-APC, PD-1- PE-Cy7, PD-1- Percp-Cy5.5, CTLA-4-PE, CTLA-4-FITC, ki67-Alexa Fluor 488 and their respective isotype controls were purchased from Biolegend. Recombinant human IFN-γ (R&D Systems) was used at 200 ng/ml. Anti-PD-1 Ab (Nivolumab from Bristol-Myers Squibb), anti-Tim-3 (clone 2E2 from Biolegend) and isotype were used at 10µg/ml.

Liu Z., McMichael E.L., Shayan G., Li J., Chen K., Srivastava R., Kane L.P., Lu B, & Ferris R.L. (2018). Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(18), 4529-4538.

+ Open protocol

+ Expand

Comprehensive NK cell phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs from subjects were resuspended in PBS buffer and were incubated with directly conjugated antibodies for 30 min at 4°C. The cells were washed with 1× PBS before flow cytometry analysis. Antibodies used included anti-human CD3-BV786, CD19-BVAPC-H7, CD16-BV711, CD69 PE-CF594, CD57-BV421, PD-1-APC, CD70-PE, CD160-AF488, 2B4-AF700, CTLA-4-PE, TIM-3-FITC, 7-AAD (BD Biosciences, San Diego, CA, USA), CD56-BV510, BTLA-PE-CY7, CD39-APC (BioLegend, San Diego, CA, USA), TIGIT-PE-Cy7 (Ebioscience, San Diego, CA, USA), along with the corresponding isotype controls. NK cells were gated as CD3⁻CD14⁻CD19⁻CD56⁺CD16⁺, CD3⁻CD14⁻CD19⁻CD56⁺CD16⁻, or CD3⁻CD14⁻CD19⁻CD56⁻CD16⁺. Data were acquired with the LSR Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software version 10.5 (Tree Star, Ashland, OR, USA).

Deng M., Zeng Y., Liu Y., Wang X., Chen N., Zhang M., Jiang M., Zhao H, & Du J. (2024). Increased PD-1+ NK Cell Subset in the Older Population. International Journal of General Medicine, 17, 651-661.

+ Open protocol

+ Expand

Comprehensive Treg Immunophenotyping and Functional Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs (1 × 10⁶) were stained with CD4 PerCP, CD25 Alexa488, and FoxP3 PE for the identification of Treg populations (BD FoxP3 staining protocol, according to the manufacturer’s instructions). CD4 PerCP, CD25 Alexa488, CD27 APC, and CD45RA PE-Cy7 (eBioscience) were used to assess surface phenotype. In some experiments, CD39 APC, PD1 PE-Cy7, and glucocorticoid-induced tumor necrosis factor receptor (GITR) APC (Biolegend) were analyzed on Treg populations. Intracellular cytokine staining was performed to determine IFN-γ and IL-10 production at the single-cell level as described previously using anti-human IFN-γ-PE-Cy7 and anti-human IL-10 APC (both from Biolegend). For the evaluation of TGF-β secretion, the surface expression of the latency-associated peptide (LAP) protein (anti-human LAP-PE-Cy7, Biolegend) was assessed. For all flow cytometry experiments, sample acquisition and analysis were carried out on a FACSCanto flow cytometer using the BD FACSDiva software (BD Biosciences). Negative control samples were incubated with irrelevant, isotype-matched mAbs in parallel with experimental samples.

Angerami M.T., Suarez G.V., Vecchione M.B., Laufer N., Ameri D., Ben G., Perez H., Sued O., Salomón H, & Quiroga M.F. (2017). Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection. Frontiers in Immunology, 8, 528.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!